| Identification | Back Directory | [Name]
YP001 | [CAS]
1192171-69-9 | [Synonyms]
YP001
PXL007
PLX007
EYP-001
Vonafexor
Vonafexor(PLX007,EYP-001)
2-Benzofurancarboxylic acid, 4-chloro-5-[4-[(2,6-dichlorophenyl)sulfonyl]-1-piperazinyl]- | [Molecular Formula]
C19H15Cl3N2O5S | [MDL Number]
MFCD32701906 | [MOL File]
1192171-69-9.mol | [Molecular Weight]
489.76 |
| Chemical Properties | Back Directory | [Boiling point ]
680.5±65.0 °C(Predicted) | [density ]
1.604±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
3.05±0.30(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Vonafexor (EYP001) is an orally active, non-steroidal and selective FXR agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research[1][2]. | [References]
[1] Erken R, et al. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study. J Viral Hepat. 2021 Dec;28(12):1690-1698. DOI:10.1111/jvh.13608
[2] Hui RW, et al. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials. Expert Opin Emerg Drugs. 2022 Jun;27(2):127-140. DOI:10.1080/14728214.2022.2074977
[3] Joly S, et al. The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells. J Hepatol 66(1):S690.
[4] Fiorucci S,et al. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH) [published online ahead of print, 2020 Jun 19]. Expert Opin Investig Drugs. 2020;1-10. DOI:10.1080/13543784.2020.1763302 |
|
|